Abstract
Due to their high prevalence, non-alcoholic fatty liver disease (NAFLD), insulin resistance (IR) and hepatitis C virus (HCV) infection are bound to cohabit. However, the relationship between these 3 entities is complex and multilayered. HCV, particularly genotype 3, may induce a “viral” steatosis, morphologically indistinguishable from the steatosis of NAFLD but with different implications and prognosis. On the other hand, epidemiological and experimental data show that patients with HCV have a higher risk of developing IR and, in susceptible individuals, type 2 diabetes (T2D). In patients with HCV, T2D increases fibrosis progression rate, increases the incidence of HCC, worsens liver-related outcomes and worsens response to interferon-α based therapy. We conclude by discussing a possible increased incidence of cardiovascular events in HCV patients.
Keywords: Fibrosis, hepatitis C virus, non-alcoholic fatty liver disease, steatosis.
Graphical Abstract
Reviews on Recent Clinical Trials
Title:Insulin Resistance, Non-alcoholic Fatty Liver Disease and Hepatitis C Virus Infection
Volume: 9 Issue: 3
Author(s): Nicolas Goossens and Francesco Negro
Affiliation:
Keywords: Fibrosis, hepatitis C virus, non-alcoholic fatty liver disease, steatosis.
Abstract: Due to their high prevalence, non-alcoholic fatty liver disease (NAFLD), insulin resistance (IR) and hepatitis C virus (HCV) infection are bound to cohabit. However, the relationship between these 3 entities is complex and multilayered. HCV, particularly genotype 3, may induce a “viral” steatosis, morphologically indistinguishable from the steatosis of NAFLD but with different implications and prognosis. On the other hand, epidemiological and experimental data show that patients with HCV have a higher risk of developing IR and, in susceptible individuals, type 2 diabetes (T2D). In patients with HCV, T2D increases fibrosis progression rate, increases the incidence of HCC, worsens liver-related outcomes and worsens response to interferon-α based therapy. We conclude by discussing a possible increased incidence of cardiovascular events in HCV patients.
Export Options
About this article
Cite this article as:
Goossens Nicolas and Negro Francesco, Insulin Resistance, Non-alcoholic Fatty Liver Disease and Hepatitis C Virus Infection, Reviews on Recent Clinical Trials 2014; 9 (3) . https://dx.doi.org/10.2174/1574887109666141216101939
DOI https://dx.doi.org/10.2174/1574887109666141216101939 |
Print ISSN 1574-8871 |
Publisher Name Bentham Science Publisher |
Online ISSN 1876-1038 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
3D QSAR Studies on Substituted Benzimidazole Derivatives as Angiotensin II-AT<sub>1</sub> Receptor Antagonist
Current Computer-Aided Drug Design Jak2 and Reactive Oxygen Species: A Complex Relationship
Current Chemical Biology Impact of Metabolic Surgery on Type 2 Diabetes Mellitus, Cardiovascular Risk Factors, and Mortality: A Review
Current Hypertension Reviews Use of N-acetyl-cysteine to Prevent Nephrotoxicity Associated with Iodinated Contrast Agents
Current Drug Therapy The Role of Notch Signaling Pathway in Epithelial-Mesenchymal Transition (EMT) During Development and Tumor Aggressiveness
Current Drug Targets Cultured Adult Animal Neurons and Schwann Cells Give Us New Insights into Diabetic Neuropathy
Current Diabetes Reviews Angiotensin II: Role in Skeletal Muscle Atrophy
Current Protein & Peptide Science New Therapies in SLE
Recent Patents on Inflammation & Allergy Drug Discovery Antidiabetic Effect of Polyphenolic Extracts from Selected Edible Plants as α-Amylase, α -Glucosidase and PTP1B Inhibitors, and β Pancreatic Cells Cytoprotective Agents - A Comparative Study
Current Topics in Medicinal Chemistry Age-related Changes in Pharmacodynamics: Focus on Drugs Acting on Central Nervous and Cardiovascular Systems
Current Drug Metabolism Animal Models of Obesity and Metabolic Syndrome: Potential Tools for Alzheimers Disease Research
Current Alzheimer Research Proteomics Approaches to Understand Linkage Between Alzheimer’s Disease and Type 2 Diabetes Mellitus
CNS & Neurological Disorders - Drug Targets Incidence of Type 2 Diabetes Among Patients Exposed to the Combination of Pravastatin and Paroxetine
Current Drug Safety Urotensin II: Molecular Mechanisms of Biological Activity
Current Protein & Peptide Science Neutrophil Gelatinase-Associated Lipocalin (NGAL) as a Biomarker for Acute Kidney Injury
Recent Patents on Biomarkers Role of the heme oxygenase-adiponectin-atrial natriuretic peptide axis in renal function
Current Pharmaceutical Design Establishing Genomic/Transcriptomic Links Between Alzheimer’s Disease and Type 2 Diabetes Mellitus by Meta-Analysis Approach
CNS & Neurological Disorders - Drug Targets Seaweed Polysaccharides - New Therapeutic Insights Against the Inflammatory Response in Diabetic Nephropathy
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Renal Protective Effect of Metabolic Therapy in Patients with Coronary Artery Disease and Diabetes: From Bench to Bed Side
Current Pharmaceutical Design Molecular Genetics and Epidemiology of Japanese Type 1 Diabetes
Current Pharmacogenomics